Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE)

NCT02726503 is registered in ClinicalTrials.gov with Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan as lead sponsor.

NCT NCT02726503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02726503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE)
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase
Phase 2
Overall status
Completed
Start date
April 4, 2016
Completion date
March 20, 2020
Enrollment
39 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid cancer